ULTRAVATE (halobetasol propionate) by Lacer is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. Approved for psoriasis. First approved in 2015.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
ULTRAVATE (halobetasol propionate) is a potent topical corticosteroid lotion approved for treating plaque psoriasis. The drug modulates signaling, immune function, inflammation, and protein regulation, though its precise mechanism in psoriasis remains incompletely understood. It represents a well-established topical therapy in the dermatology space.
Product is at peak commercial performance with stable market position; moderate-sized commercial team likely supports dermatology-focused sales and marketing activities.
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Worked on ULTRAVATE at Lacer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
ULTRAVATE offers stable, mid-career opportunity in established dermatology commercialization with focus on market maintenance and customer relationship management. As the product approaches LOE (2033), career growth may require redeployment to next-generation assets or pivot to lifecycle extension strategies.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo